Cartiva, Inc.

Cartiva, Inc. develops innovative solutions for joint health, focusing on osteoarthritis treatments. Their flagship product, the Cartiva Synthetic Cartilage Implant, aims to improve joint function and alleviate pain in patients with degenerative arthritis. Founded in 2011, Cartiva, Inc.

is based in Alpharetta, US, and specializes in joint health solutions. The company was acquired in August 2018 by Wright Medical Group, Inc. for USD 435 mn in cash, with the transaction completed in October 2018. Eman Magdy is the founder, with a history in developing medical devices.

Cartiva has engaged in 7 total deals focusing on innovative orthopedic solutions. Cartiva is primarily focused on the development and commercialization of innovative solutions for joint health, specifically targeting osteoarthritis. The company's flagship product, the Cartiva Synthetic Cartilage Implant (SCI), is designed to restore joint function and relieve pain in patients suffering from hallux rigidus, a form of degenerative arthritis in the big toe. Released to the market in 2016, the SCI mimics the properties of natural cartilage, allowing for better mobility compared to traditional treatments.

Cartiva's offerings cater to orthopedic surgeons and healthcare providers across North America, Europe, and select international markets, enhancing patient care. Cartiva generates revenue primarily through the sale of its synthetic cartilage implants, operating a direct-to-consumer model that facilitates transactions with healthcare providers and surgical centers. Their business structure includes partnerships with orthopedic surgical practices, where the implants are purchased and subsequently used in surgeries. Pricing plans for their flagship product reflect the advanced technology and research invested in its development, with payments typically made on a per-unit basis linked to the surgeries performed.

Revenue is further supported through ongoing collaborations with hospitals and orthopedic clinics, contributing to a sustainable income model. Cartiva, Inc. plans to utilize its recent acquisition funding to expand its product offerings and market reach. The company is focused on developing new orthopedic solutions that will be launched in the upcoming years.

Additionally, Cartiva aims to enter new markets, specifically targeting expansion in Europe and Asia by 2025. The acquisition by Wright Medical Group, Inc. is expected to facilitate these growth initiatives, providing the necessary resources and strategic direction to enhance their market presence.